UBS Group’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

UBS Group’s Portfolio SGYP Stock Details SGYP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-9,900	Closed	-$1K	–	8533
2018 Q4	$1K	Buy	+9,900	New	+$6.5K	﹤0.01%	7971

Other funds holding SGYP

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group's SGYP Position: Q1 2019 in Review

UBS Group sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q1 2019, closing a stake of 367,480 shares — an estimated $42K sold.

UBS Group first reported a position in SGYP in Q4 2014 and held it in 17 quarters. The position peaked at $8.18M in Q3 2017. 12 funds tracked by Wall St. Rank hold SGYP as of Q1 2019.

UBS Group reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q1 2019 after selling out during the quarter.
UBS Group sold 367,480 Synergy Pharmaceuticals, Inc Common Stock shares in Q1 2019, an estimated $42K.
UBS Group first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q4 2014 and held it in 17 quarters.
UBS Group's Synergy Pharmaceuticals, Inc Common Stock position peaked at $8.18M in Q3 2017.
12 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q1 2019.

Based on UBS Group's 13F filing for Q1 2019, filed 14 May 2019.